Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2018

06.06.2018 | short review

Update of clinical highlights presented at the 2017 American Society of Hematology Meeting

Focus multiple myeloma

verfasst von: Dr. Sabine Burger, PD Dr. Niklas Zojer, Univ.-Prof. Dr. Heinz Ludwig

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Summary

At the 2017 American Society of Hematology Meeting promising data were presented reflecting the impressing advances of clinical research in multiple myeloma. In fit patients eligible for autologous stem cell transplantation new induction regimens showed high response and minimal residual disease negativity rates. Again the important role of autologous stem cell transplantation was pointed out especially for patients with high risk cytogenetics. In the relapsed setting intensified combination therapies are related with improvement of PFS (progression free survival) and even OS (overall survival). Concerning maintenance therapy significant benefits in all standard, high and ultra-high risk groups of patients could be demonstrated. New developements like Selinexor, Filanesib and CAR (chimeric antigen receptor) T cells showed impressing results in a heavily pretreated population.
Literatur
1.
Zurück zum Zitat Gay FM, et al. A randomized study of Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Cyclophosphamide-Dexamethasone induction in newly diagnosed myeloma patients eligible for transplant: high efficacy in high- and standard risk patients. Blood. 2017;130:4541. Gay FM, et al. A randomized study of Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Cyclophosphamide-Dexamethasone induction in newly diagnosed myeloma patients eligible for transplant: high efficacy in high- and standard risk patients. Blood. 2017;130:4541.
2.
Zurück zum Zitat Cavo M, et al. Autologous stem cell transplantation versus Bortezomib-Melphalan-Prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMNO2/HO95 study. Blood. 2017;130:397. CrossRef Cavo M, et al. Autologous stem cell transplantation versus Bortezomib-Melphalan-Prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMNO2/HO95 study. Blood. 2017;130:397. CrossRef
3.
Zurück zum Zitat Qazilbash MH, et al. A randomized phase III trial of Busulfan + Melphalan vs Melphalan alone for multiple myeloma. Blood. 2017;130:399. Qazilbash MH, et al. A randomized phase III trial of Busulfan + Melphalan vs Melphalan alone for multiple myeloma. Blood. 2017;130:399.
4.
Zurück zum Zitat Jackson G, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130:436. Jackson G, et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood. 2017;130:436.
5.
Zurück zum Zitat Fernández R, et al. Maintenance treatment with Lenalidomide for multiple myeloma increases the proportion of MRD negative (flow‑/PET-CT-) patients. Blood. 2017;130:3098. Fernández R, et al. Maintenance treatment with Lenalidomide for multiple myeloma increases the proportion of MRD negative (flow‑/PET-CT-) patients. Blood. 2017;130:3098.
6.
Zurück zum Zitat Facon T, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–10. CrossRefPubMedPubMedCentral Facon T, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131:301–10. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mateos MV, et al. Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (pts) ineligible for transplant (ALCYONE). Blood. 2017;130:LBA-4. CrossRef Mateos MV, et al. Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (pts) ineligible for transplant (ALCYONE). Blood. 2017;130:LBA-4. CrossRef
8.
Zurück zum Zitat Zweegman S, et al. Ixazomib-thalidomide low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; initial results from the randomized phase II HOVON-126/Nmsg 21.13 trial. Blood. 2017;130:433. CrossRef Zweegman S, et al. Ixazomib-thalidomide low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; initial results from the randomized phase II HOVON-126/Nmsg 21.13 trial. Blood. 2017;130:433. CrossRef
9.
Zurück zum Zitat Larocca A, et al. Impact of bortezomib- or lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the Gimema-MM-03-05 and EMN01 trials. Blood. 2017;130:744. Larocca A, et al. Impact of bortezomib- or lenalidomide-based induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the Gimema-MM-03-05 and EMN01 trials. Blood. 2017;130:744.
10.
Zurück zum Zitat Stewart KA, et al. Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd): final analysis from the randomized phase 3 Aspire trial. Blood. 2017;130:743. Stewart KA, et al. Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd): final analysis from the randomized phase 3 Aspire trial. Blood. 2017;130:743.
11.
Zurück zum Zitat Yong K, et al. Carfilzomib, cyclophosphamide and dexamethasone (KCD) versus bortezomib, cyclophosphamide and dexamethasone (VCD) for treatment of first relapse or primary refractory multiple myeloma (MM): first final analysis of the phase 2 Muk Five study. Blood. 2017;130:835. Yong K, et al. Carfilzomib, cyclophosphamide and dexamethasone (KCD) versus bortezomib, cyclophosphamide and dexamethasone (VCD) for treatment of first relapse or primary refractory multiple myeloma (MM): first final analysis of the phase 2 Muk Five study. Blood. 2017;130:835.
12.
Zurück zum Zitat Montefusco V, et al. Bortezomib/cyclophosphamide/dexamethasone versus lenalidomide/cyclophosphamide/dexamethasone in multiple myeloma patients at first relapse: final results of a phase III study. Blood. 2017;130:836. CrossRef Montefusco V, et al. Bortezomib/cyclophosphamide/dexamethasone versus lenalidomide/cyclophosphamide/dexamethasone in multiple myeloma patients at first relapse: final results of a phase III study. Blood. 2017;130:836. CrossRef
13.
Zurück zum Zitat Garderet L, et al. A multicenter open label phase II study of pomalidomide, cyclophosphamide and dexamethasone in relapse multiple myeloma patients initially treated with lenalidomide, bortezomib and dexamethasone. Blood. 2017;130:837. CrossRef Garderet L, et al. A multicenter open label phase II study of pomalidomide, cyclophosphamide and dexamethasone in relapse multiple myeloma patients initially treated with lenalidomide, bortezomib and dexamethasone. Blood. 2017;130:837. CrossRef
Metadaten
Titel
Update of clinical highlights presented at the 2017 American Society of Hematology Meeting
Focus multiple myeloma
verfasst von
Dr. Sabine Burger
PD Dr. Niklas Zojer
Univ.-Prof. Dr. Heinz Ludwig
Publikationsdatum
06.06.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0407-z

Weitere Artikel der Ausgabe 2/2018

memo - Magazine of European Medical Oncology 2/2018 Zur Ausgabe